3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
24
Fallopian Tube Neoplasms
20
Breast Neoplasms
10
Carcinoma, Ovarian Epithelial
8
Sarcoma
6
Neoplasms
4
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Sarcoma, Kaposi
2
Sarcoma, Ewing
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Multi-centric Castleman's Disease
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Leiomyosarcoma
2
Hodgkin Disease
2
Burkitt Lymphoma
2
Acquired Immunodeficiency Syndrome
2
AIDS-related Kaposi sarcoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Vaccinia
1
Uterine Cervical Neoplasms
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
1
Recurrence
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Interventions
Paclitaxel
8
Hyperthermic Intraperitoneal Chemotherapy
6
Mitomycin
5
Cisplatin
5
Fluorouracil
4
Bevacizumab
4
Oxaliplatin
3
Leucovorin
3
Doxorubicin
3
Cytoreduction Surgical Procedures
3
Carboplatin
3
Blood Specimen Collection
3
sodium thiosulfate
2
pembrolizumab
2
Standard of Care
2
Laparoscopy
2
strattice
1
soluble LAG-3 protein, human
1
relacorilant
1
oregovomab
1
olaparib
1
nilotinib
1
liposomal doxorubicin
1
irinotecan sucrosofate
1
dehydroftorafur
1
avelumab
1
X-Rays
1
Topotecan
1
Taxes
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Peritoneal Neoplasms
×
liposomal doxorubicin
×
1 year
×
Clear all
NCT07213804
2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3
Recruiting
1,080 enrolled